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SUMMARY AT A GLANCE
We analysed a primary care clinical cohort database to investigate respiratory symptoms and
healthcare use in the 10 years prior to a diagnosis of pulmonary fibrosis. Utilisation progressively





Background and objective: Temporal trends of healthcare use in the period before a diagnosis of
pulmonary fibrosis are poorly understood. We investigated trends in respiratory symptoms and lower
respiratory healthcare resource utilisation (HRU) in the 10 years prior to diagnosis.
Methods: We analysed a primary care clinical cohort database (UK Optimum Patient Care Research
Database) and assessed patients aged ≥40 years who had an electronically coded diagnosis of
pulmonary fibrosis between 2005–2015 and a minimum two years continuous medical records prior to
diagnosis. Exclusion criteria consisted of electronic codes for recognised causes of pulmonary fibrosis
such as CTD, sarcoidosis or extrinsic allergic alveolitis.
Results: Data for 2223 patients were assessed. Over the 10 years prior to diagnosis of pulmonary
fibrosis there was a progressive increase in HRU across multiple lower respiratory (LR)-related
domains. Five years before diagnosis, 18% of patients had multiple healthcare contacts for LR
complaints; this increased to 79% in the year before diagnosis, with 38% of patients having five or
more healthcare contacts.
Conclusion: There are opportunities to diagnose pulmonary fibrosis at an earlier stage; research into
case-finding algorithms and strategies to educate primary care physicians is required.
 
Short title: Earlier diagnosis of pulmonary fibrosis
 




Idiopathic pulmonary fibrosis (IPF) is a form of chronic, progressive fibrotic lung disease. It affects 14–
43 people per 100,000, with a mean age at presentation of 66 years [1–4]. Median post-diagnostic
survival of IPF is 2–5 years, with a 5-year survival of 20% [3,5]. There is a lack of public awareness,
yet IPF kills more people per year than leukaemia or ovarian cancer, with the number affected
increasing [6].
 
Historically, treatment of IPF was limited to symptom management and palliation, potentially providing
little motivation for earlier diagnosis. However, even without approved pharmacological treatment,
delayed access to specialist interstitial lung disease (ILD) services increases risk of death [7]. Recent
approval of two effective anti-fibrotic treatments (nintedanib and pirfenidone), which slow disease
progression, heralds a new era for patients with IPF [8,9]. Thus, the importance of an early and
accurate diagnosis is clear [10].
 
While early diagnosis and treatment of IPF is now widely advocated [11,12], how this can be achieved
remains less clear. Precision medicine and genomic techniques are being widely researched to
identify blood- or lung-specific biomarkers to enhance IPF diagnosis [13]. However, such
methodologies are available only in specialist centres, access to which first requires suspicion, or
diagnosis, of pulmonary fibrosis. A challenge to the specialist referral pathway is the limited
understanding of the natural history of pulmonary fibrosis; it is thought patients may be symptomatic
for five years before a formal diagnosis is made [14].
 
As all patients with pulmonary fibrosis (including IPF) in the United Kingdom (UK) present first in
primary care, primary care medical records provide an important resource for understanding temporal
patterns of healthcare system utilisation (HRU) prior to diagnosis. This study assessed trends in HRU




Data source and study approvals
The Optimum Patient Care Research Database (OPCRD) contains anonymised, longitudinal medical
records for patients registered at primary care practices across the UK [17]. It includes demographic,
lifestyle, diagnostic and HRU data recorded from primary and secondary care. At the time of the study
it comprised records for approximately 2.5 million patients registered across 525 UK-based primary
care practices.
 
The OPCRD is approved by the Health Research Authority of the UK NHS for clinical research use
(REC reference: 15/EM/0150). Access was approved by the OPCRD’s Anonymised Data Ethics and
Protocol Transparency Committee (approval code, ADEPT0616). The study protocol was developed
by an independent steering committee of the Respiratory Effectiveness Group (REG) and registered
with the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP;
registration number EUPAS12086) [18].
 
Study design and population
This historical cohort study included an observation period of 2–10 years (as available) prior to an
index date at which patients received a first diagnostic code for pulmonary fibrosis. Data extraction
cut-off date was December 31st 2015. Cases were identified from diagnostic (Read) code lists
developed by the REG ILD Working Group and aligned with published IPF-related research conducted
in the UK [6,14]. Acknowledging variations in coding practice between healthcare professionals, cases
were labelled as “pulmonary fibrosis-clinical syndrome” (PFCS) in the presence of a code considered
diagnostic of pulmonary fibrosis and the absence of codes associated with ILD, such as a connective
tissue disease (CTD), sarcoidosis or extrinsic allergic alveolitis (EAA). A subpopulation of patients with
only IPF-specific diagnostic codes—here termed “IPF clinical syndrome” (IPFCS)—was identified.
Diagnostic codes used as inclusion criteria for the PFCS and IPFCS cohorts are provided in
Supplementary Table S1 [6,14]. Codes contributing to PFCS or IPFCS were recorded in primary and
secondary care.
 
Eligible patients were aged ≥40 years at diagnosis and diagnosed with PFCS between 2005–2015.
Patients with less than two years of continuous medical records immediately prior to diagnosis were
excluded. Exclusion of patients with CTD, sarcoidosis and EAA (codes in Supplementary Table S2)




Characteristics of the study population: demographic (age, sex, anthropomorphic measures); lifestyle
(smoking history); clinical features (lung function [FVC, FEV1/FVC] recorded closest to diagnosis);
common comorbidities (chronic obstructive pulmonary disease [COPD], asthma and lung cancer, as
defined by codes rather than functional tests); and use of obstructive lung disease (OLD)
pharmacotherapy in the year preceding PFCS diagnosis.
 
Healthcare resource utilisation
Temporal trends in respiratory symptoms were evaluated by assessment of population-level per-
patient annualised cough events coded through primary care consultations over 10 years prior to
PFCS diagnosis. Functional impairment was evaluated using the mini-Medical Research Council
(mMRC) score captured through a systematic data capture protocol. Availability of mMRC scores
reflected patients’ willingness to participate in routne data collection rather than their clinical situation.
 
10-year trends in lower respiratory (LR) HRU were evaluated through annualised per-patient rates of
coded events, including: primary care consultations, chest radiography (CXR), hospitalisations and
emergency room attendances, and antibiotics and acute oral steroid prescriptions for an LR complaint.
LR complaint codes included those for LR tract infections (bronchitis, tracheitis, pneumonia), non-
infective LR conditions (chronic respiratory failure), and respiratory symptoms (breathlessness, cough,
wheeze).
 
Opportunities for earlier PFCS diagnosis were explored by evaluating unique patients with 0, 1, 2, 3,
4, ≥5 LR-related primary care contacts in each 1-year period in the decade preceding PFCS
diagnosis. Prevalence of potential differential pulmonary diagnoses (COPD, asthma and lung cancer)
at time of PFCS diagnosis, and their proximity to PFCS diagnosis, were also explored.
 
Statistical analysis
Summary statistics (n [%]) for patient characteristics at time of PFCS or IPFCS diagnosis were
generated using STATA (version 14). Joinpoint Trend Analysis software from the Surveillance
Research Programme of the US National Cancer Institute (available at
http://surveillance.cancer.gov/joinpoint) was used to test whether non-segmented or segmented
regression curves best described the evolution of temporal trends for outcomes (LR symptoms and
HRU) over the ten-year period prioto diagnosis [19]. Joinpoints (inflection points) indicated timepoints








The PFCS cohort comprised more men (62.9%) than women, with a mean (standard deviation [SD])
age of 72.6 (9.7) years. Two-thirds (67.2%) were current/former smokers. Cardiorespiratory conditions
were the most common comorbidities at time of PFCS diagnosis: ischaemic heart disease (32.4%),
COPD (22.6%), lung cancer (18.0%), asthma (13.9%). Mean (SD) FVC was 2.9 (5.7) L and FEV1/FVC
ratio was 0.78 (0.1). Almost one-quarter of patients (23.2%) received a prescription for a short-acting
beta2-agonist one year prior to PFCS diagnosis (Table 1). PFCS and IPFCS patient characteristics
were broadly similar (Tables 1 and Supplementary Table S3, respectively). In patients with OLD,
COPD diagnosis occurred at a mean (SD) of 5.1 (6.7) years, and asthma at a mean (SD) of 12.1
(14.1) years, prior to PFCS diagnosis. 40% of patients received asthma diagnosis within five years
prior to PFCS diagnosis (60% within 10 years). COPD diagnosis occurred at 4.6 (6.2) years, and
asthma at 13.0 (17.4) years, prior to IPFCS diagnosis.
 
Functional impairment (assessed by mMRC) score prior to PFCS diagnosis were available for 47% of
patients. When stratified by time between mMRC assessment and PFCS diagnosis, no pronounced
temporal trends were observed, although a slight reduction in patients without signs of functional
impairment was apparent over the 10-year study period (Supplementary Figure S2).
 
Healthcare resource utilisation
The mean pre-observation period for patients with non-missing HRU data ranged from 6–8 years.
There was marked increase in cough events in lead up to PFCS diagnosis (Figure 2). Mean (SD)
annual per-patient cough event rate increased 10-fold (from 0.06 [0.3] per patient per year [pppy] at
10 years and 0.58 [0.6] pppy one year prior to diagnosis). Joinpoint regression analysis identified a
significant increase in cough events two years prior to PFCS diagnosis (APCs for years 10–2 vs 2–1:
19.67% vs 115.09%; P=0.0002). In the IPFCS cohort cough event rates increased from 0.05 to 0.13
pppy over the 10-year period (data not shown).
 
Trends in LR HRU demonstrated that mean (SD) primary care LR consultations increased from 0.4
(1.3) pppy at 10 years prior to PFCS diagnosis, to 4.5 (1.6) pppy one year prior to diagnosis (Figure 3
and Table 2). APCs for LR consultations significantly increased two years prior to PFCS diagnosis
(APCs for years 10–2 vs 2–1: 19.96% vs 199.72%; P=0.0002). Antibiotic and acute oral steroid
prescriptions for LR events increased over the 10-year period (0.08 [0.3] to 0.81 [0.7] pppy and 0.02
[0.2] to 1.07 [0.7] pppy, respectively). APCs for antibiotic and acute steroid prescriptions significantly
increased two years (APCs for years 10–2 vs 2–1: 20.70% vs 118.72%; P=0.0002) and three years
(APCs for years 10–3 vs 3–1: 36.92% vs 151.27%; P=0.0024) prior to PFCS diagnosis, respectively.
These trends were consistent in the IPFCS cohort (Supplementary Figure S3 and Table S4).
 
APC for secondary care contacts for LR complaints (hospital admissions or ER attendances) was
0.00% until two years prior to PFCS diagnosis. For years 2–1 prior to PFCS diagnosis, an APC of
700.00% was observed (Figure 3 and Table 2). This was consistent in the IPFCS cohort (
Supplementary Figure S3 and Table S4). A 3-fold increase in pneumonia in the two years immediately
prior to PFCS diagnosis was also observed (data not shown). Chest X-rays (CXRs) increased 10-fold
from 10 years to one year prior to PFCS diagnosis (mean [SD] CXRs: 0.03 [0.2] to 0.40 [0.5] pppy,
respectively; Figure 3 and Table 2). APC for CXRs significantly increased two years prior to PFCS
diagnosis (APCs for years 10–2 vs 2–1: 18.64% vs 216.07%; P=0.0002). In the IPFCS cohort,
however, APC for CXRs significantly increased one year earlier, i.e. three years prior to IPFCS
diagnosis (Supplementary Figure S3 and Table S4).
 
All-cause primary care consultations were examined to explore whether increases in LR consultations
reflected a general escalation in all-cause HRU due to aging. LR consultations accounted for 10% and
35% of all-cause consultations 10 years and one year prior to PFCS diagnosis, respectively. APC for
all-cause consultations significantly increased two years prior to PFCS diagnosis (APCs for years 10–
2 vs 2–1: 11.90% vs 46.76%; P=0.0004). This increase was driven by LR consultations (APCs for
years 10–2 vs 2–1: 19.96% vs 199.72%; P=0.0002), while APC for non-LR consultations was constant
(11.03%) (Figure S4). The contribution of LR consultations to all-cause consultations was evident in
the IPFCS cohort (data not shown).
 
Ten years prior to PFCS diagnosis, 18% of patients visited primary care for an LR reason. Of these
patients, only 6.3% consulted ≥2 times and 1.5% ≥5 times. Five years later, approximately 30% of
patients consulted ≥1 times for an LR complaint, 14.4% ≥2 times and 3.8% ≥5 times. One year prior to
PFCS diagnosis, almost all patients (99.9%) consulted ≥1 times for an LR complaint, 78.8% ≥2 times
and 38.0% ≥5 times (Figure 4 and Supplementary Table S5). Consistent with this, APCs for two, three,
four, and five or more LR consultations significantly increased two years prior to PFCS diagnosis
(APCs for 10–2 vs 2–1 years: 12.60% vs 85.47% (P=0.0018), 20.96% vs 67.79% (P=0.0104), 21.95%
vs 141.43% (P=0.0007), and 25.35% vs 309.71% (P=0.0002), respectively). 
 
DISCUSSION
Our findings show a significant increase in HRU across several domains prior to a PFCS diagnosis:
cough, LR consultations, antibiotic and acute steroid prescriptions, and CXR. Eighteen percent of
patients made multiple primary care visits for LR complaints five years before PFCS diagnosis;
increasing to almost 80% one year before diagnosis, with 38% having five or more primary care
contacts. Therefore, opportunities exist for earlier referral for pulmonary fibrosis suspected in primary
care.
 
Whilst the natural history of OLD is growing [20], that of fibrotic lung diseases remains limited.
Research into fibrotic lung disease has traditionally been restricted to evaluations conducted within
specialist centres; large-scale primary care databases offer an opportunity to study more widely
representative and generalisable populations.
 
We analysed a high-quality dataset widely used in primary care studies [17,20]. Anthropomorphic and
lung function measures are consistent with previous IPF cohorts [6,8,9,21]. PFCS diagnosis was
based on codes diagnostic for pulmonary fibrosis and the absence of codes associated with ILD.
While potentially including patients with a form of pulmonary fibrosis other than IPF, a subgroup
analysis of codes specific for IPF demonstrated comparability. These patients need specialist referral
for investigation irrespective of final diagnosis. Additional studies are required to validate specific
diagnostic groups, including the correlation of primary care diagnostic codes with specialist care
diagnosis.  
 
Our findings extend those of Hewson et al. who identified increasing breathlessness and cough in the
five years prior to IPFCS diagnosis [14]. We identified significant increases in cough events and LR-
related HRU two years preceding PFCS diagnosis. This may reflect symptom progression from minor
to moderate/severe, with symptoms affecting quality resulting in increased HRU. Increases in LR
consultations, antibiotic and acute oral steroid prescriptions suggests infective episodes may
precipitate HRU and lead to subsequent diagnosis. Alternatively, acute prescriptions may represent
empirical trials by primary care physicians following repeat patient attendances for persistent
symptoms of uncertain aetiology.
 
Thirty eight percent of patients had five or more LR consultations one year preceding IPF diagnosis.
This suggests repeated primary care attendances are required for specialist referral. Given the
potential for misdiagnosis, we investigated the relationship between respiratory comorbidities and
PFCS diagnosis. COPD and asthma diagnoses occurred at five and 12 years before PFCS diagnosis,
respectively. While these timelines may suggest alternative respiratory diagnoses, this could reflect
misdiagnosis of initial functional impairment due to early-onset PFCS.
 
Limitations in our data and framework conditions potentially restrict our interpretations. For example,
spirometry is not routine in primary care, with COPD or asthma patients more likely to undergo
spirometry testing. Secondary care data requires manual reporting and entry into primary care
records, resulting in under-reporting and under-estimation of HRU from secondary care. A limitation to
the interpretation of any relationship between PFCS diagnosis and preceding comorbidities is that
comorbidities were captured through codes rather than functional tests. Miscoding represents a
source of potential misdiagnosis. Another consideration is framework conditions that determine drug
prescribing policies which change over time and may influence HRU in the lead up to diagnosis. Our
analysis did not account for this potential covariate.
 
Nevertheless, patients consistently report dissatisfaction with time taken to diagnosis [15,16]. Studies
investigating how to effectively increase awareness of pulmonary fibrosis among primary care
physicians are required. This may include re-emphasis of routine lung auscultation to check for
crackles in older patients presenting with repeated LR complaints over a short time period. In older
populations, a joint spirometric and lung auscultation approach may have value for obstructive and
fibrotic lung disease diagnosis. Future research should seek to link primary and secondary care data
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Figure 1. Pulmonary fibrosis clinical syndrome (PFCS) eligibility flow diagram.
OPCRD: Optimum Patient Care Research Database; CTD: connective tissue disease; RA: rheumatoid
arthritis
 
Figure 2. Joinpoint regression analysis of cough-related events over 10 years prior to PFCS
diagnosis.
APC: annual percent change; Joinpoint: point of change in regression trends; pppy: per patient per
year; PFCS: pulmonary fibrosis clinical syndrome; Number of patients with non-missing data in year
10 to year 1 prior to PFCS diagnosis: 1474, 1533, 1598, 1686, 1772, 1861, 1944, 2019, 2087, 2223;
Mean pre-observation period: 8 years.
 
Figure 3. Joinpoint regression analysis of temporal HRU trends over 10 years prior to PFCS
diagnosis.
Temporal HRU trends in the 10 years prior to PFCS diagnosis for A) lower respiratory (LR)
consultations, B) acute antibiotic prescriptions, C), acute steroid prescriptions, D) LR hospital
contacts, and E) chest X-rays. APC: annual percent change; Joinpoint: point of change in regression
trends; pppy: per patient per year; PFCS: pulmonary fibrosis clinical syndrome; Number of patients
1
with non-missing data in year 10 to year 1 prior to PFCS diagnosis: 1474, 1533, 1598, 1686, 1772,
1861, 1944, 2019, 2087, 2223; mean pre-observation period: 8 years.
Figure 4. Joinpoint regression analysis of LR healthcare contacts over 10 years prior to PFCS
diagnosis.
Temporal HRU trends showing percentage of patients with A) 0, B) 1, C) 2, D) 3, E) 4, and F) ≥5 LR
consultations in the 10 years prior to PFCS diagnosis; APC: annual percent change; Joinpoint: point of
change in regression trends; PFCS, pulmonary fibrosis clinical syndrome; Number of patients with
non-missing data in year 10 to year 1 prior to PFCS diagnosis: 1474, 1533, 1598, 1686, 1772, 1861,
1944, 2019, 2087, 2223; Mean pre-observation period: 8 years 
 Table 1. Baseline characteristics at time of PFCS diagnosis
 
Characteristic n = 2,223
Male sex, n (%) 1,399 (62.9)
Age at index date (years), mean (SD) 72.6 (9.7)








Ischaemic heart disease 720 (32.4)
Heart failure 249 (11.2)
Hypertension 118 (5.3)
Myocardial infarction 258 (11.6)
Lung Cancer 401 (18.0)
Sleep Apnoea 18 (0.8)
GERD* 170 (7.7)
Anxiety and depression 55 (2.5)






Without comorbid COPD n = 245
FVC (L), mean (SD) 2.9 (5.7)
FEV1/FVC ratio, mean (SD) 0.78 (0.1)
With comorbid COPD n = 74
FVC (L), mean (SD) 2.5 (0.9)
FEV1/FVC ratio, mean (SD) 0.72 (0.2)
 
PFCS: pulmonary fibrosis clinical syndrome; * Active comorbidities defined as recorded within two years prior to diagnosis; SABA: short-




Table 2. Temporal trends in healthcare resource utilisation in the 10 years prior to PFCS diagnosis
 
1
 Year prior to PFCS diagnosis
 10 9 8 7 6 5 4 3 2 1
n (non-missing) 1474 1533 1598 1686 1772 1861 1944 2019 2087 2223














































































































PFCS: pulmonary fibrosis clinical syndrome; SD: standard deviation; pppy: per patient per year; * Lower respiratory (LR)
code recorded on same day as inpatient admission; † LR code recorded within 14 days of an inpatient admission; Sen:
sensitivity; Number of patients with non-missing data in year 10 to year 1 prior to PFCS diagnosis: 1474, 1533, 1598,
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Figure S2. Functional impairment (mMRC score) over 10 years prior to PFCS diagnosis
 
PFCS: pulmonary fibrosis clinical syndrome; Number of patients with non-missing data in year 10 to year 1 prior to PFCS diagnosis:
183, 233, 289, 377, 648, 784, 861, 946, 999, 1034; Mean pre-observation period: 6 years.      
 




     
 
 




Temporal HRU trends in the 10 years prior to IPFCS diagnosis for A) lower respiratory (LR) consultations, B) acute antibiotic
prescriptions, C), acute steroid prescriptions, D) LR hospital contacts, and E) chest X-rays. APC: annual percent change; Joinpoint:
point of change in regression trends; IPFCS, idiopathic pulmonary fibrosis clinical syndrome; pppy: per patient per year; Number of
patients with non-missing data in year 10 to year 1 prior to IPFCS diagnosis: 473, 488, 513, 540, 570, 601, 629, 658, 708, 743; Mean
pre-observation period: 8 years.
 
 
Figure S4- Relative contribution of LR consultations to all-cause consultations over 10 years
prior to PFCS diagnosis
 
 
     
 
 
     
 
Temporal HRU trends in the 10 years prior to PFCS diagnosis for A) all-cause consultations, B), lower respiratory (LR) consultations, C)
non-LR consultations, D) LR consultations as a proportion of all-cause consultations; APC: annual percent change; Joinpoint: point of
change in regression trends; pppy: per patient per year; Number of patients with non-missing data in year 10 to year 1 prior to PFCS









Table S1- Diagnostic Code list for PFCS and IPFCS cohorts
 
Read Code Read Term
H563100* Diffuse pulmonary fibrosis
H563200* Pulmonary fibrosis
H563.00 Idiopathic fibrosing alveolitis
H563.12† Cryptogenic fibrosing alveolitis
H563z00 Idiopathic fibrosing alveolitis NOS
H563300 Usual interstitial pneumonitis
H563.13 Idiopathic pulmonary fibrosis
XE0Yb Idiopathic pulmonary fibrosis
X102v Usual interstitial pneumonitis
H563z Idiopathic fibrosing alveolitis NOS
 
PFCS cohort included all Read Codes shown above
IPFCS cohort included all Read Codes except those designated *





Table S2- Exclusion Read code list for pulmonary fibrosis aetiologies
 
Read code Description
N040G00 Rheumatoid arthritis of subtalar joint
N040D00 Rheumatoid arthritis of knee
N04y012 Fibrosing alveolitis associated with rheumatoid arthritis
N043100 Acute polyarticular juvenile rheumatoid arthritis
N040R00 Rheumatoid nodule
N040C00 Rheumatoid arthritis of sacro-iliac joint
N043300 Monarticular juvenile rheumatoid arthritis
2G27.00 O/E-hands-rheumatoid spindling
N040000 Rheumatoid arthritis of cervical spine
Nyu1200 [X]Other specified rheumatoid arthritis
N040A00 Rheumatoid arthritis of DIP joint of finger
N040400 Rheumatoid arthritis of acromioclavicular joint
N040700 Rheumatoid arthritis of wrist
N040800 Rheumatoid arthritis of MCP joint
N044.12 Nodular fibrositis of chronic rheumatic disease
N040S00 Rheumatoid arthritis - multiple joint
Nyu1100 [X]Other seropositive rheumatoid arthritis
N040M00 Rheumatoid arthritis of IP joint of toe
N040F00 Rheumatoid arthritis of ankle
N044.00 Chronic post-rheumatic arthropathy
N040K00 Rheumatoid arthritis of 1st MTP joint
N040N00 Rheumatoid vasculitis
N040P00 Seronegative rheumatoid arthritis
N040900 Rheumatoid arthritis of PIP joint of finger
N040H00 Rheumatoid arthritis of talonavicular joint
N040T00 Flare of rheumatoid arthritis
N040J00 Rheumatoid arthritis of other tarsal joint
N042200 Rheumatoid nodule
N040300 Rheumatoid arthritis of sternoclavicular joint
N042.00 Other rheumatoid arthropathy + visceral/systemic involvement
N043.00 Juvenile rheumatoid arthritis - Still's disease
N047.00 Seropositive errosive rheumatoid arthritis
N040L00 Rheumatoid arthritis of lesser MTP joint
N042000 Rheumatic carditis
N045500 Juvenile rheumatoid arthritis
N043200 Pauciarticular juvenile rheumatoid arthritis
14G1.00 H/O: rheumatoid arthritis
N040E00 Rheumatoid arthritis of tibio-fibular joint
N04y000 Rheumatoid lung
F396400 Myopathy due to rheumatoid arthritis
N040100 Other rheumatoid arthritis of spine
N040200 Rheumatoid arthritis of shoulder
N04..00  Rheumatoid arthritis and other inflammatory polyarthropathy
N04X.00 Seropositive rheumatoid arthritis, unspecified
N040500 Rheumatoid arthritis of elbow
N043z00 Juvenile rheumatoid arthritis NOS
N040600 Rheumatoid arthritis of distal radio-ulnar joint




N042100 Rheumatoid lung disease
Nyu1000 [X]Rheumatoid arthritis+involvement/other organs or systems
Nyu1G00 [X]Seropositive rheumatoid arthritis, unspecified
N043000 Juvenile rheumatoid arthropathy unspecified
F371200 Polyneuropathy in rheumatoid arthritis
N042z00 Rheumatoid arthropathy + visceral/systemic involvement NOS
N001000 Progressive systemic sclerosis
Q471100 Scleroderma in newborn
F396600 Myopathy due to scleroderma
Nyu4500 [X]Other forms of systemic sclerosis
M210z00 Circumscribed scleroderma NOS
N001.12 Systemic sclerosis
H572.00 Lung disease with systemic sclerosis
N001.00 Scleroderma
M210400 Linear scleroderma
M210000 Unspecified circumscribed scleroderma
N001100 CREST syndrome
M210.00 Circumscribed scleroderma
M154200 Lupus erythematosus migrans
N....00             Musculoskeletal and connective tissue diseases
N000000 Disseminated lupus erythematosus
Nyu4400 [X]Other dermatomyositis
N003.11 Poikilodermatomyositis
F396100 Myopathy due to disseminated lupus erythematosus
N003100 Dermatopolymyositis in neoplastic disease
N....11                Connective tissue diseases
K01x400 Nephrotic syndrome in systemic lupus erythematosus
N000400 Systemic lupus erythematosus with pericarditis
H57y100 Lung disease with polymyositis
Nyu4300 [X]Other forms of systemic lupus erythematosus
N000z00 Systemic lupus erythematosus NOS
F371000 Polyneuropathy in disseminated lupus erythematosus
H57y400 Lung disease with systemic lupus erythematosus
Nz...00                Musculoskeletal and connective tissue diseases NOS
Nyu4F00 [X]Mixed connective tissue disease
Myu7800 [X]Other local lupus erythematosus
M154600 Lupus erythematosus unguium mutilans
M154300 Lupus erythematosus nodularis
M154.00 Lupus erythematosus
N000.00 Systemic lupus erythematosus
Nyu4800 [X]Dermato(poly)myositis in neoplastic disease CE
M154000 Lupus erythematosus chronicus
Nyu4E00 [X]Dermatopolymyositis, unspecified
M154700 Subacute cutaneous lupus erythematosus
N00..11  Collagen diseases
N000500 Neonatal lupus erythematosus
M154400 Lupus erythematosus profundus
N00z.00 Collagen disease NOS
M154100 Discoid lupus erythematosus
N004.00 Polymyositis
N000300 Systemic lupus erythematosus with organ or sys involv
M154z00 Lupus erythematosus NOS
M154500 Lupus erythematosus tumidus
N003X00 Dermatopolymyositis, unspecified
N003000 Juvenile dermatomyositis
N00y.00 Other specified diffuse collagen diseases
K01x411 Lupus nephritis
N003.00 Dermatomyositis
F4D3300 Eyelid discoid lupus erythematosus
AD5..00 Sarcoidosis
AD50.00 Sarcoidosis of lung
AD51.00 Sarcoidosis of lymph nodes
AD52.00 Sarcoidosis of lung with sarcoidosis of lymph nodes
AD53.00 Sarcoidosis of skin
AD54.00 Sarcoidosis of inferior turbinates
AD55.00 Sarcoid arthropathy
Cyu0600 [X]Sarcoidosis of other and combined sites
F013.00 Meningitis due to sarcoidosis
F326300 Multiple cranial nerve palsies in sarcoidosis
F374900 Polyneuropathy in sarcoidosis
F396500 Myopathy due to sarcoidosis
G558300 Sarcoid heart disease
G5y7.00 Sarcoid myocarditis
H57y200 Pulmonary sarcoidosis
J63A.00 Hepatic granulomas in sarcoidosis
N233200 Myositis in sarcoidosis
Nyu8900 [X]Myositis in sarcoidosis classified elsewhere
H4...11              Pneumoconioses
H40..00  Coal workers' pneumoconiosis
H42..00  Silica and silicate pneumoconiosis
H420.00 Talc pneumoconiosis
H42z.00 Silica pneumoconiosis NOS
H43..00  Pneumoconiosis due to other inorganic dust
H43z.00 Pneumoconiosis due to inorganic dust NOS
H45..00  Pneumoconiosis NOS
Hyu4000 [X]Pneumoconiosis due to other dust containing silica
Hyu4100 [X]Pneumoconiosis due to other specified inorganic dusts
H41..00  Asbestosis
H41z.00 Asbestosis NOS
H35..00  Extrinsic allergic alveolitis
H35y.00 Other allergic alveolitis
H35yz00 Other allergic alveolitis NOS
H35z.00 Allergic alveolitis and pneumonitis NOS
H35z000 Allergic extrinsic alveolitis NOS
H35zz00 Allergic alveolitis and pneumonitis NOS
 
 
Table S3- Baseline characteristics of patients in idiopathic pulmonary fibrosis clinical
syndrome (IPFCS) cohort
 
Baseline characteristic IPFCS cohort(n = 743)
Male sex, n (%) 484 (65.1)
Age at index date (years), mean (SD) 72.2 (9.6)








Ischaemic heart disease 218 (29.3)
Heart failure 81 (10.9)
Hypertension 29 (3.9)
Myocardial infarction 72 (9.7)
Lung cancer 109 (14.7)
Sleep apnoea 6 (0.8)
GERD* 40 (5.4)
Anxiety and depression 18 (2.4)
Time from comorbidity diagnosis to IPFCS diagnosis (years), mean (SD)
COPD 4.6 (6.2)
Asthma 13.0 (17.4)
Any prescriptions in year prior to IPFCS diagnosis, n (%)
1
1
SABA, n (%) 131 (17.6)
SAMA, n (%) 43 (5.8)
ICS, n (%) 54 (6.3)
ICS/LABA, n (%) 54 (6.3)
Lung Function IPFCS Cohort Subgroup(n = 76)
FVC (L), mean (SD)  
All patients 2.5 (0.9)
Patients with comorbid COPD 2.6 (0.9)
Patients without comorbid COPD 3.1 (6.8)
FEV1/FVC, mean (SD)  
All patients 0.81 (0.1)
Patients with comorbid COPD 0.70 (0.2)
Patients without comorbid COPD 0.81 (0.1)
IPFCS: idiopathic pulmonary fibrosis clinical syndrome; † Comorbidities defined as ever-recorded; * Active comorbidities defined as
recorded within the last 2 years; SABA: short-acting beta-agonist; SAMA: short-acting antimuscarinic; ICS: inhaled corticosteroid;
GERD: gastroesophogeal reflux disease; mMRC: mini Medical Research Council  
 
 
Table S4-Temporal trends in healthcare resource utilisation over 10 years prior to IPFCS
diagnosis (IPFCS cohort)
 
 Year prior to IPFCS diagnosis
 10 9 8 7 6 5 4 3 2 1
n (non-missing) 473 488 513 540 570 601 629 658 708 743




































































































Diagnostics, mean (SD) per patient per year


















PFCS: pulmonary fibrosis clinical syndrome; SD: standard deviation; * Lower respiratory (LR) code recorded on same day as inpatient
admission; sen, sensitivity; † LR code recorded within 14 days of an inpatient admission; number of patients with non-missing data in




Table S5- Distribution of lower respiratory healthcare consultations over 10 years prior to
PFCS diagnosis
 Year prior to PFCS diagnosis
 10 9 8 7 6 5 4 3 2 1
N, non-
missing 1474 1533 1598 1686 1772 1861 1944 2019 2087 2223
























































≥4 12 (0.8) 16 (1.1) 26 (1.7) 23 (1.4) 31 (1.8) 44 (2.5) 56 (3.0) 66 (3.5) 93 (4.4) 228(10.2)








PFCS: pulmonary fibrosis clinical syndrome; Number of patients with non-missing data in year 10 to year 1 prior to PFCS diagnosis:
1474, 1533, 1598, 1686, 1772, 1861, 1944, 2019, 2087, 2223; Mean pre-observation period: 8 years.  
 
